SG11201502493XA - Orexin receptor antagonists which are [ortho bi (hetero )aryl]-[2-(meta bi (hetero )aryl)-pyrrolidin-1-yl]-methanone derivatives - Google Patents
Orexin receptor antagonists which are [ortho bi (hetero )aryl]-[2-(meta bi (hetero )aryl)-pyrrolidin-1-yl]-methanone derivativesInfo
- Publication number
- SG11201502493XA SG11201502493XA SG11201502493XA SG11201502493XA SG11201502493XA SG 11201502493X A SG11201502493X A SG 11201502493XA SG 11201502493X A SG11201502493X A SG 11201502493XA SG 11201502493X A SG11201502493X A SG 11201502493XA SG 11201502493X A SG11201502493X A SG 11201502493XA
- Authority
- SG
- Singapore
- Prior art keywords
- hetero
- aryl
- pyrrolidin
- ortho
- meta
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12188019 | 2012-10-10 | ||
EP13157809 | 2013-03-05 | ||
PCT/IB2013/059233 WO2014057435A1 (en) | 2012-10-10 | 2013-10-09 | Orexin receptor antagonists which are [ortho bi (hetero )aryl]-[2-(meta bi (hetero )aryl)-pyrrolidin-1-yl]-methanone derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201502493XA true SG11201502493XA (en) | 2015-04-29 |
Family
ID=49765598
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201502493XA SG11201502493XA (en) | 2012-10-10 | 2013-10-09 | Orexin receptor antagonists which are [ortho bi (hetero )aryl]-[2-(meta bi (hetero )aryl)-pyrrolidin-1-yl]-methanone derivatives |
Country Status (16)
Country | Link |
---|---|
US (1) | US9493446B2 (en) |
EP (1) | EP2906553B1 (en) |
JP (1) | JP6244365B2 (en) |
KR (1) | KR102151288B1 (en) |
CN (1) | CN104703980B (en) |
AR (1) | AR092955A1 (en) |
AU (1) | AU2013328301A1 (en) |
BR (1) | BR112015007516A2 (en) |
CA (1) | CA2885180C (en) |
EA (1) | EA201500399A1 (en) |
IL (1) | IL238052A0 (en) |
MX (1) | MX2015004638A (en) |
PH (1) | PH12015500627A1 (en) |
SG (1) | SG11201502493XA (en) |
TW (1) | TW201414727A (en) |
WO (1) | WO2014057435A1 (en) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY169986A (en) | 2012-06-04 | 2019-06-19 | Idorsia Pharmaceuticals Ltd | Benzimidazole-proline derivatives |
EP2970241A1 (en) | 2013-03-12 | 2016-01-20 | Actelion Pharmaceuticals Ltd. | Azetidine amide derivatives as orexin receptor antagonists |
DK3077389T3 (en) | 2013-12-03 | 2017-11-13 | Idorsia Pharmaceuticals Ltd | CRYSTALLIC FORM OF (S) - (2- (6-CHLOR-7-METHYL-1H-BENZO [D] IMIDAZOL-2-YL) -2-METHYLPYRROLIDIN-1-YL) (5-METHOXY-2- (2H- 1,2,3-TRIAZOL-2-YL) PHENYL) METHANON AND ITS USE AS OREXIN RECEPTOR ANTAGONISTS |
UA119151C2 (en) * | 2013-12-03 | 2019-05-10 | Ідорсія Фармасьютікалз Лтд | Crystalline salt form of (s)-(2-(6-chloro-7-methyl-1 h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist |
US9914721B2 (en) | 2013-12-04 | 2018-03-13 | Idorsia Pharmaceuticals Ltd | Use of benzimidazole-proline derivatives |
JP2017024990A (en) * | 2013-12-13 | 2017-02-02 | 大正製薬株式会社 | Oxazolidine and oxazinan derivative |
WO2016100157A2 (en) * | 2014-12-19 | 2016-06-23 | Merck Sharp & Dohme Corp. | 6,5-bicyclic octahydropyrrolopyridine orexin receptor antagonists |
CN106349228B (en) | 2015-07-17 | 2019-07-09 | 广东东阳光药业有限公司 | Substituted quianzolinones and its preparation method and application |
US10370380B2 (en) | 2015-11-23 | 2019-08-06 | Sunshine Lake Pharma Co., Ltd. | Octahydropyrrolo[3,4-c]pyrrole derivatives and uses thereof |
CN106986859B (en) * | 2016-01-20 | 2020-02-11 | 广东东阳光药业有限公司 | Indole derivatives and uses thereof |
EP3594202B1 (en) | 2017-03-08 | 2021-08-11 | Takeda Pharmaceutical Company Limited | Substituted pyrrolidine compound and use thereof |
CN108794454B (en) * | 2017-04-27 | 2023-08-15 | 广东东阳光药业股份有限公司 | Preparation method of imidazole ring compound |
ES2892161T3 (en) * | 2017-05-03 | 2022-02-02 | Idorsia Pharmaceuticals Ltd | Preparation of 2-([1,2,3]triazol-2-yl)-benzoic acid derivatives |
WO2019018795A1 (en) * | 2017-07-20 | 2019-01-24 | Yumanity Therapeutics | Compounds and uses thereof |
CA3083000A1 (en) | 2017-10-24 | 2019-05-02 | Yumanity Therapeutics, Inc. | Compounds and uses thereof |
EP3700522A4 (en) | 2017-10-26 | 2021-08-11 | Southern Research Institute | Oxadiazoles and thiadiazoles as tgf-beta inhibitors |
JP2021522253A (en) | 2018-04-25 | 2021-08-30 | ユマニティ セラピューティクス,インコーポレーテッド | Compounds and their use |
EP3917616A1 (en) | 2019-01-31 | 2021-12-08 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
WO2023218023A1 (en) | 2022-05-13 | 2023-11-16 | Idorsia Pharmaceuticals Ltd | Thiazoloaryl-methyl substituted cyclic hydrazine-n-carboxamide derivatives |
US11912675B1 (en) | 2023-10-11 | 2024-02-27 | King Faisal University | N'-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)-3,4-dimethoxybenzimidamide as an antimicrobial compound |
US11919872B1 (en) | 2023-10-11 | 2024-03-05 | King Faisal University | N′-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)benzimidamide as an antimicrobial compound |
US11897850B1 (en) | 2023-10-11 | 2024-02-13 | King Faisal University | N′-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)-4-methoxybenzimidamide as an antimicrobial compound |
US11891366B1 (en) | 2023-10-12 | 2024-02-06 | King Faisal University | 4-methoxy-n′-(2-(5-phenyl-1,3,4-oxadiazol-2-ylthio)acetoxy)benzimidamide as an antimicrobial compound |
Family Cites Families (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001247569A (en) | 1999-08-12 | 2001-09-11 | Japan Tobacco Inc | Pyrrolidine derivative or piperidine derivative and its medicinal use |
AUPQ253199A0 (en) | 1999-08-30 | 1999-09-23 | Fujisawa Pharmaceutical Co., Ltd. | Non-prostanoid prostaglandin I2-agonist |
WO2001096302A1 (en) | 2000-06-16 | 2001-12-20 | Smithkline Beecham P.L.C. | Piperidines for use as orexin receptor antagonists |
WO2002044172A1 (en) | 2000-11-28 | 2002-06-06 | Smithkline Beecham P.L.C. | Morpholine derivatives as antagonists of orexin receptors |
CA2446396A1 (en) | 2001-05-05 | 2002-11-14 | Smithkline Beecham P.L.C. | N-aroyl cyclic amines |
EP1435955A2 (en) | 2001-05-05 | 2004-07-14 | SmithKline Beecham P.L.C. | N-aroyl cyclic amine derivatives as orexin receptor antagonists |
KR20040029326A (en) | 2001-06-28 | 2004-04-06 | 스미스클라인비이참피이엘시이 | N-aroyl cyclic amine derivatives as orexin receptor antagonists |
GB0115862D0 (en) | 2001-06-28 | 2001-08-22 | Smithkline Beecham Plc | Compounds |
GB0124463D0 (en) | 2001-10-11 | 2001-12-05 | Smithkline Beecham Plc | Compounds |
GB0127145D0 (en) | 2001-11-10 | 2002-01-02 | Smithkline Beecham | Compounds |
GB0130393D0 (en) | 2001-12-19 | 2002-02-06 | Smithkline Beecham Plc | Compounds |
GB0130335D0 (en) | 2001-12-19 | 2002-02-06 | Smithkline Beecham Plc | Compounds |
DE10240818A1 (en) | 2002-08-30 | 2004-05-13 | Grünenthal GmbH | Substituted 2-pyrrolidin-2-yl [1,3,4] oxadiazole derivatives |
ES2273083T3 (en) | 2002-09-18 | 2007-05-01 | Glaxo Group Limited | N-AROILAMINES CYCLES AS ANTAGONISTS OF OREXIN RECEPTORS. |
GB0225938D0 (en) | 2002-11-06 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
GB0225944D0 (en) | 2002-11-06 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
GB0225884D0 (en) | 2002-11-06 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
AR044586A1 (en) | 2003-06-04 | 2005-09-21 | Aventis Pharma Sa | ARIL PRODUCTS - HETEROAROMATICOS, COMPOSITIONS THAT CONTAIN THEM AND THEIR USE |
GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
AU2005250077B2 (en) | 2004-03-01 | 2011-06-09 | Idorsia Pharmaceuticals Ltd | Substituted 1,2,3,4-tetrahydroisoquinoline derivatives |
US20050272784A1 (en) | 2004-05-07 | 2005-12-08 | Xiaobing Li | Inhibitors of bacterial Type III protein secretion systems |
EP1604989A1 (en) | 2004-06-08 | 2005-12-14 | Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft | DPP-IV inhibitors |
US7269781B2 (en) | 2004-06-25 | 2007-09-11 | Hewlett-Packard Development Company, L.P. | Discrete universal denoising with reliability information |
US20060019975A1 (en) | 2004-07-23 | 2006-01-26 | Pfizer Inc | Novel piperidyl derivatives of quinazoline and isoquinoline |
GB0510142D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds A1 |
HUP0500920A2 (en) * | 2005-10-05 | 2007-07-30 | Richter Gedeon Nyrt | Oxadiazole derivatives, process for their preparation and their use |
US20090082394A1 (en) | 2006-03-15 | 2009-03-26 | Actelion Pharmaceuticals, Ltd. | Tetrahydroisoquinoline Derivatives to Enhance Memory Function |
US8618102B2 (en) | 2006-07-14 | 2013-12-31 | Merck Sharp & Dohme Corp. | Bridged diazepan orexin receptor antagonists |
CA2658764A1 (en) * | 2006-07-20 | 2008-01-24 | Mehmet Kahraman | Benzothiophene inhibitors of rho kinase |
WO2008011453A2 (en) * | 2006-07-20 | 2008-01-24 | Amgen Inc. | SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF LLβ-HSD-1 |
RU2447070C2 (en) | 2006-08-15 | 2012-04-10 | Актелион Фармасьютиклз Лтд | Azetine compounds as orexin receptor antagonists |
WO2008038251A2 (en) | 2006-09-29 | 2008-04-03 | Actelion Pharmaceuticals Ltd | 3-aza-bicyclo[3.1.0]hexane derivatives |
EP2094685B1 (en) | 2006-12-01 | 2011-01-19 | Actelion Pharmaceuticals Ltd. | 3-heteroaryl (amino or amido)-1- (biphenyl or phenylthiazolyl) carbonylpiperdine derivatives as orexin receptor inhibitors |
PE20081229A1 (en) | 2006-12-01 | 2008-08-28 | Merck & Co Inc | DIAZEPAM OREXIN RECEPTOR ANTAGONISTS REPLACED |
CL2007003827A1 (en) | 2006-12-28 | 2008-09-26 | Actelion Pharmaceuticals Ltd | COMPOUNDS DERIVED FROM N- (2-AZA-BICYCLE (3.1.0) HEX-3-ILMETIL) AMIDA; AND ITS USE TO PREVENT OR TREAT DEPRESSION, NEUROSIS, SCHIZOPHRENIA, ANXIETY, ADDICTIONS, EPILEPSY, PAIN, HEART DISEASES, AMONG OTHERS. |
WO2008087611A2 (en) | 2007-01-19 | 2008-07-24 | Actelion Pharmaceuticals Ltd | Pyrrolidine- and piperidine- bis-amide derivatives |
CL2008000836A1 (en) | 2007-03-26 | 2008-11-07 | Actelion Pharmaceuticals Ltd | Thiazolidine derivative compounds, orexin receptor antagonists; pharmaceutical composition that includes them; and its use in the treatment of emotional neurosis, severe depression, psychotic disorders, Alzheimer's, parkinson's, pain, among others. |
ATE483707T1 (en) | 2007-05-14 | 2010-10-15 | Actelion Pharmaceuticals Ltd | 2-CYCLOPROPYLTHIAZOLE DERIVATIVES |
US7741347B2 (en) | 2007-05-17 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
CA2687821C (en) | 2007-05-22 | 2015-04-14 | Boehringer Ingelheim International Gmbh | Benzimidazolone chymase inhibitors |
AU2008260647A1 (en) | 2007-05-23 | 2008-12-11 | Merck Sharp & Dohme Corp. | Cyclopropyl pyrrolidine orexin receptor antagonists |
KR101140520B1 (en) | 2007-06-01 | 2012-04-30 | 에프. 호프만-라 로슈 아게 | Piperidine-amide derivatives |
TW200911242A (en) | 2007-07-03 | 2009-03-16 | Glaxo Group Ltd | Novel compounds |
EP2164847B1 (en) | 2007-07-03 | 2011-09-14 | Actelion Pharmaceuticals Ltd. | 3-aza-bicyclo[3.3.0]octane compounds |
GB0712888D0 (en) | 2007-07-03 | 2007-08-15 | Glaxo Group Ltd | Novel compounds |
CN101687321B (en) | 2007-07-05 | 2012-08-08 | 松下电器产业株式会社 | Robot arm control device and control method, robot and control program |
WO2009016564A2 (en) | 2007-07-27 | 2009-02-05 | Actelion Pharmaceuticals Ltd | 2-aza-bicyclo[3.3.0]octane derivatives |
DE602008004265D1 (en) | 2007-07-27 | 2011-02-10 | Actelion Pharmaceuticals Ltd | TRANS-3-azabicyclo-Ä3.1.0Ü-HEXANE DERIVATIVES |
AR067665A1 (en) | 2007-07-27 | 2009-10-21 | Actelion Pharmaceuticals Ltd | DERIVATIVES OF TRANS-3- AZA-BICYCLE (3.1.0) HEXANO |
EP2207778A2 (en) | 2007-09-24 | 2010-07-21 | Actelion Pharmaceuticals Ltd. | Pyrrolidines and piperidines as orexin receptor antagonists |
PE20091010A1 (en) | 2007-10-10 | 2009-08-08 | Actelion Pharmaceuticals Ltd | TETRAHYDROQUINOLINE DERIVATIVES |
CA2706839C (en) | 2007-12-18 | 2015-10-20 | Actelion Pharmaceuticals Ltd | Aminotriazole derivatives as alx agonists |
JP2011512400A (en) | 2008-02-21 | 2011-04-21 | アクテリオン ファーマシューティカルズ リミテッド | 2-Aza-bicyclo [2.2.1] heptane derivatives |
GB0806536D0 (en) | 2008-04-10 | 2008-05-14 | Glaxo Group Ltd | Novel compounds |
WO2010004507A1 (en) | 2008-07-07 | 2010-01-14 | Actelion Pharmaceuticals Ltd | Thiazolidine compounds as orexin receptor antagonists |
WO2010038200A1 (en) | 2008-10-01 | 2010-04-08 | Actelion Pharmaceuticals Ltd | Oxazolidine compounds as orexin receptor antagonists |
RU2011119217A (en) | 2008-10-14 | 2012-11-27 | Актелион Фармасьютикалз Лтд | DERIVATIVES OF PHENETHYLAMIDE AND THEIR HETEROCYCLIC ANALOGUES |
EP2349269A4 (en) | 2008-10-21 | 2012-04-25 | Merck Sharp & Dohme | 2,5-disubstituted piperidine orexin receptor antagonists |
JP2012509912A (en) | 2008-11-26 | 2012-04-26 | グラクソ グループ リミテッド | New compounds |
JP2012509911A (en) | 2008-11-26 | 2012-04-26 | グラクソ グループ リミテッド | New compounds |
EP2358711A1 (en) | 2008-11-26 | 2011-08-24 | Glaxo Group Limited | Piperidine derivatives useful as orexin receptor antagonists |
EP2370426A1 (en) | 2008-12-02 | 2011-10-05 | Glaxo Group Limited | N-{[(ir,4s,6r-3-(2-pyridinylcarbonyl)-3-azabicyclo [4.1.0]hept-4-yl]methyl}-2-heteroarylamine derivatives and uses thereof |
TW201031407A (en) | 2008-12-02 | 2010-09-01 | Glaxo Group Ltd | Novel compounds |
GB0823467D0 (en) | 2008-12-23 | 2009-01-28 | Glaxo Group Ltd | Novel Compounds |
EP2413941A4 (en) | 2009-04-03 | 2012-10-10 | Merck Sharp & Dohme | Renin inhibitors |
EP2421850A1 (en) | 2009-04-24 | 2012-02-29 | Glaxo Group Limited | 3 -azabicyclo [4.1.0]heptanes used as orexin antagonists |
CN102414207B (en) | 2009-06-09 | 2015-09-30 | 埃科特莱茵药品有限公司 | Fluorinated aminotriazole derivatives |
JP5848251B2 (en) | 2009-10-23 | 2016-01-27 | ヤンセン ファーマシューティカ エヌ.ベー. | Fused heterocyclic compounds as orexin receptor modulators |
EP2491038B1 (en) | 2009-10-23 | 2016-04-06 | Janssen Pharmaceutica N.V. | Disubstituted octahy - dropyrrolo [3,4-c]pyrroles as orexin receptor modulators |
JP5847087B2 (en) | 2009-10-23 | 2016-01-20 | ヤンセン ファーマシューティカ エヌ.ベー. | Fused heterocyclic compounds as orexin receptor modulators |
WO2011090911A1 (en) | 2010-01-19 | 2011-07-28 | Amgen Inc. | Amino heteroaryl compounds as beta-secretase modulators and methods of use |
WO2012039717A1 (en) | 2010-09-24 | 2012-03-29 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
MY169986A (en) | 2012-06-04 | 2019-06-19 | Idorsia Pharmaceuticals Ltd | Benzimidazole-proline derivatives |
EP2970241A1 (en) | 2013-03-12 | 2016-01-20 | Actelion Pharmaceuticals Ltd. | Azetidine amide derivatives as orexin receptor antagonists |
-
2013
- 2013-10-09 CA CA2885180A patent/CA2885180C/en active Active
- 2013-10-09 US US14/434,997 patent/US9493446B2/en active Active
- 2013-10-09 TW TW102136619A patent/TW201414727A/en unknown
- 2013-10-09 EA EA201500399A patent/EA201500399A1/en unknown
- 2013-10-09 BR BR112015007516A patent/BR112015007516A2/en not_active IP Right Cessation
- 2013-10-09 KR KR1020157012089A patent/KR102151288B1/en active IP Right Grant
- 2013-10-09 SG SG11201502493XA patent/SG11201502493XA/en unknown
- 2013-10-09 CN CN201380051391.3A patent/CN104703980B/en active Active
- 2013-10-09 AU AU2013328301A patent/AU2013328301A1/en not_active Abandoned
- 2013-10-09 JP JP2015536264A patent/JP6244365B2/en active Active
- 2013-10-09 WO PCT/IB2013/059233 patent/WO2014057435A1/en active Application Filing
- 2013-10-09 AR ARP130103661A patent/AR092955A1/en unknown
- 2013-10-09 EP EP13805561.1A patent/EP2906553B1/en active Active
- 2013-10-09 MX MX2015004638A patent/MX2015004638A/en unknown
-
2015
- 2015-03-20 PH PH12015500627A patent/PH12015500627A1/en unknown
- 2015-03-31 IL IL238052A patent/IL238052A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP6244365B2 (en) | 2017-12-06 |
KR102151288B1 (en) | 2020-09-03 |
EA201500399A1 (en) | 2015-09-30 |
IL238052A0 (en) | 2015-05-31 |
MX2015004638A (en) | 2015-07-14 |
BR112015007516A2 (en) | 2017-07-04 |
JP2015533157A (en) | 2015-11-19 |
CN104703980A (en) | 2015-06-10 |
CN104703980B (en) | 2017-09-22 |
CA2885180C (en) | 2021-03-02 |
CA2885180A1 (en) | 2014-04-17 |
TW201414727A (en) | 2014-04-16 |
PH12015500627A1 (en) | 2015-05-11 |
AR092955A1 (en) | 2015-05-06 |
AU2013328301A1 (en) | 2015-05-28 |
US20150252032A1 (en) | 2015-09-10 |
WO2014057435A1 (en) | 2014-04-17 |
KR20150064753A (en) | 2015-06-11 |
AU2013328301A8 (en) | 2015-06-11 |
EP2906553B1 (en) | 2019-06-26 |
US9493446B2 (en) | 2016-11-15 |
EP2906553A1 (en) | 2015-08-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL238052A0 (en) | Orexin receptor antagonists which are [ortho bi (hetero )aryl]-[2-(meta bi (hetero )aryl)-pyrrolidin-1-yl]-methanone derivatives | |
IL249578A (en) | Substituted heterocycle fused gamma carbolines | |
HK1206740A1 (en) | Substituted hetero azepinones | |
EP2862853A4 (en) | Fused heterocyclic compound | |
EP2857396A4 (en) | Fused heterocyclic compound | |
EP2857397A4 (en) | Fused heterocyclic compound | |
HK1252279A1 (en) | 5-ht3 receptor antagonists | |
ZA201304042B (en) | Spiro-oxindole mdm2 antagonists | |
HK1203201A1 (en) | Nitrogen-containing aromatic heterocyclic compound | |
EP2921480A4 (en) | Nitrogen-containing heterocyclic compound | |
AP2015008591A0 (en) | Heterocyclic compounds | |
HK1215568A1 (en) | Nitrogen-containing heterocyclic compound | |
EP2627329A4 (en) | Trpa1 receptor antagonist | |
HK1205706A1 (en) | V1a receptor agonists v1a | |
EP2874621A4 (en) | Mineralocorticoid receptor antagonists | |
HK1182097A1 (en) | 5-ht2b receptor antagonists 5-ht2b | |
EP2618666A4 (en) | Novel dihydropyrimidin-2(1h)-one compounds as neurokinin-3 receptor antagonists | |
EP2846800A4 (en) | Heterocyclic cgrp receptor antagonists | |
GB201202400D0 (en) | Nitrogen-containing heterocyclic compounds | |
GB201213699D0 (en) | Receptor antagonists II | |
GB201213698D0 (en) | Receptor antagonists II |